STOCK TITAN
  1. Home
  2. News
  3. FOXO

FOXO Technologies Inc. - FOXO STOCK NEWS

Welcome to our dedicated page for FOXO Technologies news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO Technologies stock.

FOXO Technologies Inc. (symbol: FOXO) is leading the charge in transforming the global longevity and life insurance industries through cutting-edge epigenetic technology and AI-driven solutions. Founded under the names Yousurance and Life Epigenetics, the company has redefined how we understand and measure health and aging.

FOXO’s core business revolves around commercializing longevity science by utilizing epigenetic biomarkers to assess the biological age and health status of individuals. This revolutionary approach not only impacts life insurance underwriting protocols but also engages consumers directly through an advanced platform.

With a focus on DNA methylation, FOXO leverages supervised machine learning and artificial intelligence to pinpoint molecular signs of aging and health conditions. This enables more accurate risk assessment and personalized health insights, setting new standards in the insurance sector.

Recent achievements include groundbreaking advancements in epigenetic research and the integration of AI to enhance the precision of health evaluations. The company's current projects aim to further refine these technologies and expand their application range, ensuring they remain at the forefront of innovation in their field.

Financially, FOXO Technologies Inc. is committed to sustained growth and solidifying its market presence through strategic partnerships and continual investment in research and development. Their collaborations with leading scientific institutions and industry partners underscore their commitment to excellence and innovation.

Stay updated with the latest news and developments to see how FOXO Technologies Inc. continues to shape the future of longevity and health insurance.

News

FOXO Technologies Completes Strategic Alternatives Review and Outlines Latest Progress Executing Corporate Strategy

Rhea-AI Summary
FOXO Technologies Inc. announces completion of strategic review and provides business update on progress and plans. The new management team has initiated a significant restructuring of the business, including reducing headcount expenses by approximately 65% and divesting certain assets. The company is leveraging new AI technologies to enhance efficiency and drive a new direct-to-consumer go-to-market strategy. They have been granted two key patents that will be integrated into their new consumer-focused health and wellness offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers

Rhea-AI Summary
FOXO Technologies receives Issue Notification for key patent utilizing machine learning model to determine biochemical state and medical condition using DNA epigenetic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
-
News

FOXO Technologies™ Interim CEO Mark White Provides Letter to Shareholders Outlining New AI-Enabled Direct-to-Consumer Strategy and Immediate Expense Reductions

Rhea-AI Summary
FOXO Technologies Inc. provides a letter to shareholders from the newly appointed interim CEO, Mark White, outlining the new direction for the company. The focus is on driving value through a more cost-effective go-to-market strategy, including a subscription-based app and AI technologies. The company is also exploring strategic alternatives and implementing initiatives to streamline costs and enhance the balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.31%
Tags
AI
News

FOXO Technologies Announces Agreement With Atrio Insurance

Rhea-AI Summary
FOXO Technologies Inc.™ partners with Atrio Insurance/Singular Insurance Brokerage to expand distribution of its life insurance products
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.69%
Tags
none
-
News

FOXO Technologies Inc. Announces NYSE American Acceptance of Compliance Plan

Rhea-AI Summary
FOXO Technologies receives extension for compliance with NYSE American listing standards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
none
-
News

FOXO Technologies Inc. Announces Receipt of Second Notice of Non-Compliance from NYSE American

Rhea-AI Summary
FOXO Technologies Inc. received a notice from NYSE American for non-compliance with listing standards due to low stock price. The company must effect a reverse stock split or show sustained price improvement by February 16, 2024. Accelerated delisting action may be taken if stock trades at abnormally low levels. The company also submitted a plan to regain compliance with stockholders' equity requirement by December 12, 2024. The company's business, operations, and reporting requirements with the SEC are unaffected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
News

FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity

Rhea-AI Summary
FOXO Technologies advances in utilizing epigenetic biomarker technology and AI to promote optimal health and longevity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
AI
-
News

FOXO Technologies™ Announces Second Quarter 2023 Financial Results

Rhea-AI Summary
FOXO Technologies Inc. (NYSEAM: FOXO) reported Q2 2023 financial results, focusing on capital structure streamlining, product expansion, and scientific discovery. The company completed two tender offers, raised $260,000 in a private placement, and launched Bioinformatics Services and Longevity Report™ beta product. Basic and diluted earnings per share increased, while adjusted EBITDA improved. The company will host a conference call and webcast today to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
earnings
-
News

FOXO Technologies™ Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT

Rhea-AI Summary
FOXO Technologies Inc. will report financial results for Q2 2023 on August 10, 2023. A conference call will be held at 3:15 p.m. Central time on the same day to discuss the results and recent business highlights. The call can be accessed via webcast or by dialing (888) 770-7136. The webcast will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
earnings
News

Longevity Biotech Companies GERO and FOXO Technologies™ to Embark on Joint Initiative on Artificial Intelligence and Epigenetic Data to Discover Signatures of Human Health Trajectories

Rhea-AI Summary
GERO and FOXO announce discussions for a strategic collaboration to develop an AI-driven personalized wellness and longevity recommendation engine based on proprietary epigenetic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
none

FAQ

What is the current stock price of FOXO Technologies (FOXO)?

The current stock price of FOXO Technologies (FOXO) is $0.139 as of November 4, 2024.

What is the market cap of FOXO Technologies (FOXO)?

The market cap of FOXO Technologies (FOXO) is approximately 1.9M.

What does FOXO Technologies Inc. specialize in?

FOXO Technologies Inc. specializes in applying epigenetic technology and AI to transform the life insurance industry through advanced risk assessment and consumer engagement.

How does FOXO's technology work?

FOXO uses DNA methylation and AI to identify molecular biomarkers that reveal insights into an individual's health and aging, allowing for more accurate underwriting in life insurance.

What are epigenetic biomarkers?

Epigenetic biomarkers are molecular signs found in DNA that indicate current health status and biological age, which FOXO utilizes to enhance life insurance underwriting.

How is FOXO Technologies Inc. impacting the life insurance industry?

By employing epigenetic technology and AI, FOXO is revolutionizing life insurance underwriting, making it more precise and personalized.

What are some recent achievements of FOXO Technologies Inc.?

Recent milestones include advancements in epigenetic research, development of AI-driven health assessments, and strategic partnerships to enhance their technology platform.

What is FOXO Technologies Inc.’s approach to consumer engagement?

FOXO engages consumers through a platform that provides personalized health insights based on epigenetic biomarkers, enhancing their understanding of personal health and longevity.

Who are FOXO Technologies Inc.'s partners?

FOXO collaborates with leading scientific institutions and industry partners to advance their research and technology applications in the life insurance sector.

What is DNA methylation?

DNA methylation is a biological process where methyl groups are added to DNA, affecting gene expression without altering the DNA sequence. FOXO uses this process to identify health biomarkers.

Where is FOXO Technologies Inc. headquartered?

FOXO Technologies Inc. is headquartered in Minneapolis, as indicated in their latest news release.

What is the future outlook for FOXO Technologies Inc.?

FOXO is focused on continued innovation in epigenetic technology and AI, aiming for sustained growth and expanded applications in the life insurance industry.

Stock FOXO logo
FOXO Technologies Inc.

NYSE:FOXO

FOXO Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

FOXO Stock Data

1.85M
13.63M
18.79%
2.27%
0.36%
Health Information Services
Services-commercial Physical & Biological Research
Link
United States of America
MINNEAPOLIS